GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Desacylghrelin modulates GHS-R1 receptor expression and cell differentiation in placental BeWo cells.
Coria-Caballero. Vanessa V; Jaramillo-Narvaez. Maria-de-la-Luz MD; Leon-Verdin. Ma Guadalupe MG; Martinez. Federico F; Lazo-de-la-Vega-Monroy. Maria-Luisa ML; Barbosa-Sabanero. Gloria G
Key Findings
- Desacylghrelin does not change placental cell growth or survival, but it lowers their ability to differentiate (produce hCG).
- Short‑term exposure (12‑24 h) to desacylghrelin raises GHS‑R1 (ghrelin receptor) expression, while longer exposure (48 h) reduces it.
- The ghrelin‑receptor antagonist [D‑Lys3]‑GHRP‑6 blocks the changes in receptor expression caused by desacylghrelin.
Practical Outcomes
- For biohackers, this research doesn’t provide direct guidance on using GHRP‑6 or related peptides for performance, longevity, or metabolic health. It mainly adds basic knowledge about how a specific ghrelin form interacts with placental cells, which is unlikely to translate into actionable protocols for most users.
Summary
The study looked at how a form of the hormone ghrelin that isn’t attached to a fatty acid (desacylghrelin) affects human placental cells in a dish. It found that desacylghrelin can temporarily boost the cells’ ghrelin receptor levels but later reduces them, and it also stops the cells from maturing properly. The researchers used a ghrelin‑receptor blocker called GHRP‑6 to show that these effects are linked to the receptor.
Abstract
and purpose: Ghrelin is the endogenous ligand of the growth hormone secretagogue receptor (GHS-R1). Ghrelin, and GHS-R1, may have a role in placental growth and function, and its unacylated form desacylghrelin (DAG) could be involved in fetal growth. Nevertheless, the effects of DAG on placental function, and the receptor involved in its actions, remain to be determined. We aimed to investigate the effect of DAG in placental BeWo cells viability, proliferation, differentiation, and GSH-R1 expression. BeWo cells, a human trophoblast cell line, was cultured with 3 nM DAG during 12, 24, 48, and 72 h. Cell viability, proliferation, differentiation (assessed by human Chorionic Gonadotropin quantification), and GSH-R1 expression were analyzed. To evaluate the mechanism of DAG effect on GSH-R1, 30 nM receptor antagonist ([D-Lys3]-GHRP-6) was added alone or in combination with 3 nM DAG during 12 h and 24 h. DAG has no effect on cell proliferation or viability, but it has an inhibitory effect on cell differentiation. DAG had a stimulatory effect on GSH-R1 expression at 12 and 24 h (p = 0.029 and p = 0.025, respectively). On the contrary, culture with 48 h DAG inhibits GSH-R1 expression compared to the control (p = 0.005), while GSH-R1 antagonist inhibited the effect of DAG on GSH-R1 expression. DAG also reduces intracellular (p = 0.020) and secreted (p = 0.011) hCG concentration in BeWo cells. DAG increases GHS-R1 expression, potentially mediated through GHS-R1 itself. DAG may also inhibit placental BeWo cell differentiation, suggesting a possible role of DAG in placental and fetal physiology.
Study Information
pubmed
2023
2023-07-26T00:00:00.000Z
10.1016/j.mce.2023.112035
1
32